Who are Paclitaxel + bevacizumab therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Chemotherapy combined with trastuzumab, Gemcitabine + Rituximab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paclitaxel-bevacizumab-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Paclitaxel + bevacizumab therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paclitaxel + bevacizumab therapy (Paclitaxel + bevacizumab therapy) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy + monoclonal antibody combination. Area: Oncology.

phase 3 Chemotherapy + monoclonal antibody combination β-tubulin (paclitaxel); VEGF (bevacizumab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Paclitaxel + bevacizumab therapy (Paclitaxel + bevacizumab therapy) — Japanese Foundation for Cancer Research. Paclitaxel stabilizes microtubules to inhibit cell division, while bevacizumab blocks VEGF to prevent tumor angiogenesis, combining chemotherapy with anti-angiogenic effects.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Paclitaxel + bevacizumab therapy TARGET	Paclitaxel + bevacizumab therapy	Japanese Foundation for Cancer Research	phase 3	Chemotherapy + monoclonal antibody combination	β-tubulin (paclitaxel); VEGF (bevacizumab)
Chemotherapy combined with trastuzumab	Chemotherapy combined with trastuzumab	Sun Yat-sen University	phase 3	Chemotherapy + monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
Gemcitabine + Rituximab	Gemcitabine + Rituximab	CTI BioPharma	phase 3	Chemotherapy + monoclonal antibody combination	Ribonucleotide reductase (gemcitabine); CD20 (rituximab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy + monoclonal antibody combination class)

CTI BioPharma · 1 drug in this class
Japanese Foundation for Cancer Research · 1 drug in this class
Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paclitaxel + bevacizumab therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-bevacizumab-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab